Xeljanz, Xeljanz XR (tofacitinib): Safety Communication - Safety Trial Finds Increased Risk of Blood Clots in the Lungs and Death with Higher Dose in Rheumatoid Arthritis Patients

[Posted 02/25/2019] AUDIENCE: Patient, Health Professional, Pharmacy, Rheumatology ISSUE: FDA is alerting the public that a safety clinical trial found an increased risk of blood clots in the lungs and death when a 10 mg twice daily dose of...

https://ift.tt/2NwXBeM